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Abstract. 
Gait is emerging as a potential diagnostic tool for cognitive decline. . The ‘Deep and 
Frequent Phenotyping for Experimental Medicine in Dementia Study’ (D&FP) is a 
multicentre feasibility study embedded in the United Kingdom Dementia Platform designed 
to determine participant acceptability and feasibility of extensive and repeated phenotyping to 
determine the optimal combination of biomarkers to detect disease progression and identify 
early risk of Alzheimer’s Disease.  Gait is included as a clinical biomarker. The tools to 
quantify gait in the clinic and home, and suitability for multi-centre application have not been 
examined. Six centres from the National Institute for Health Research Translational Research 
Collaboration in Dementia initiative recruited 20 individuals with early onset Alzheimer’s 
disease. Participants wore a single wearable (tri-axial accelerometer) and completed both 
clinic-based and free-living gait assessment. A series of macro (behavioural) and micro 
(spatiotemporal) characteristics were derived from the resultant data using previously 
validated algorithms. Results indicate good participant acceptability, and potential for use of 
body-worn sensors in both the clinic and the home. Recommendations for future studies have 
been provided. Gait has been demonstrated to be a feasible and suitable measure, and future 
research should examine its suitability as a biomarker in Alzheimer’s Disease. 
Keywords: Gait, wearables, phenotyping, Alzheimer’s disease, cognition, free-living 
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Introduction  
Dementia prevalence is increasing worldwide with consequential societal and economic costs 
[1]. As curative therapies have yet to be developed, research has broadened to facilitate 
preventative and interventional measures. Identification of biomarkers aims to aid early 
diagnosis [2]. This will allow people with cognitive impairment and dementia, along with 
their relatives, to optimise treatment, maintain independence and quality of life, improve 
current understanding of preclinical pathology and improve diagnostic accuracy. Gait has 
been proposed as a clinical biomarker for dementia [3].  
A relationship between gait and cognition has been established [4]. Safe gait requires 
complex cognitive processes. Reduced gait speed is linked to falls, mortality and cognitive 
decline [5]. More specific spatiotemporal measures of gait have been linked to particular 
cognitive domains; for example impaired attention and executive function are associated with 
slower pace and increased variability during walking [6]. Changes in gait can occur up to 12 
years prior to diagnosis of cognitive impairment [7]. Gait impairments in spatiotemporal 
characteristics have also been found in APOE-4 carriers, a genetic risk for Alzheimer’s 
disease [8, 9]. Therefore, gait could be a useful clinical biomarker even before the 
development of clinical dementia.  
Quantitative gait analysis provides evidence that people with dementia walk more slowly 
with increased variability and impaired temporal gait control compared to cognitively-intact 
older adults ([3, 4, 10]). Motion capture analysis systems, pressurised sensor walkways and 
accelerometers have all been useful in identifying gait impairments [11, 12]. However, the 
majority of these analytical tools require specialised laboratories, which are not widely 
available, costly and only allow infrequent assessment [13-15]. Use of wearable technology, 
such as small body-worn sensors, allows gait to be assessed in both clinic and the home 
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(termed free-living gait) [14]. Free-living gait analysis is particularly useful, as not only does 
it allow objective observation of an individual’s day-to-day gait, it also provides 
measurements of both microstructural (micro) and macrostructural (macro) characteristics of 
gait. Micro characteristics are discrete spatiotemporal gait characteristics contained in each 
walking bout (e.g. step length, step time) [16] and can be collected both in the clinic and at 
home [17]. Macro characteristics refer to the volume (e.g. total walking time, total steps) and 
pattern (e.g. variability of bout length) of walking and can only be collected over prolonged 
periods of time i.e. free-living gait assessment [16]. While micro gait characteristics are 
sensitive to changes in cognition and the brain [4], macro characteristics can provide an 
easily accessible and detailed picture of changes to an individual’s overall gait function. Free-
living gait assessment may provide a cost-effective means to assess specific gait 
characteristics and functional abilities in people with cognitive impairment. This proposal is 
supported by the successful use of wearable technology in cognitively impaired populations 
in both the clinic [18-21] and home [22]. However, to this author’s knowledge, there is no 
studies using a combined approach of clinic and free-living gait data, assessing both clinically 
relevant micro and macro outcomes.  
Gait is one of the potential clinical biomarkers investigated in the ‘Deep and Frequent 
Phenotyping for Experimental Medicine in Dementia Study’ (DFP), a multicentre feasibility 
study embedded in the United Kingdom Dementia Platform. It is designed to determine 
participant acceptability of extensive and repeated phenotyping, and to establish the 
operational practicability to inform the conduct of a full trial utilising the National Institute 
for Health Research Translational Research Collaboration in Dementia (NIHR TRC-D) 
infrastructure. The aim of this study was to determine the feasibility of conducting clinical 
and free-living gait assessments in a dementia population as part of the D&FP protocol. This 
includes establishing practical considerations for use of wearable sensors, including 
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acceptability by participants, staff training, technical considerations and limitations and 
providing recommendations for future research.  
Methods 
Participants 
Six specialist centres of excellence in the UK that constitute the NIHR Translational 
Research Collaboration in Dementia (NIHR Biomedical Research Centers or Dementia Units 
associated with the following NHS Trusts: Oxford University Hospitals (OUH), South 
London and Maudsley (SLaM), Cambridge University Hospitals (CUHT), University College 
Hospital London (UCLH), West London Mental Health Care (WLMHC) and Newcastle 
Hospitals) took part in this non-interventional multi-site study. Each aimed to recruit four 
patients with probable Alzheimer’s disease (AD), diagnosed according to National Institute 
of Aging-Alzheimer’s Association (NIA-AA) criteria [23].  
Participants inclusion criteria were: between 55 and 80; a Rosen modified Hanchinski 
ischemic score ≤4; Mini-Mental State Examination (MMSE) score above 20; healthy as 
determined by a physician; being on stable medication dose for any non-significant medical 
conditions for at least one month and stable dose for at least 3 months if treated with 
cholinesterase inhibitors and/or memantine; and able to walk independently for at least 15 
metres (with a single walking aid if required).  
Control subjects were not recruited for this pilot study. However, previous data from similar 
aged controls using the same body-worn sensors and derived gait outcomes (as seen in Table 
3 [17]) was used to make observational comparisons between controls and individuals with 
AD, as detailed in the discussion.    
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Ethics  
The study was approved by a National Research Ethics Committee London on the 19th of 
Sep 2014 – IRAS reference 14/LO/1467, IRAS project ID: 156309. All participants had 
mental capacity for informed consent.  
Protocol 
Research staff training 
All research staff attended a training day with a one-hour introductory session inclusive of 
both general and study specific gait analysis theory. This also included a brief demonstration 
of the testing protocol and data sharing platform, as well as a question and answer based 
session. All participating staff were new to the emerging field of wearable technology and 
had no previous experience of administering gait assessments. A resource pack containing 
additional training resources and materials (written and video-based standardised operating 
procedures, wearable sensors and adhesives) was provided to respective centre staff at this 
initial training day. 
Wearable technology 
Participants were asked to wear a low-cost tri-axial accelerometer-based wearable (Axivity 
AX3; Axivity, York, UK; Dimensions: 23.0mm x32.5mm x7.6mm, weight 9g) located on the 
fifth lumbar vertebra (L5; see Figure 1). The wearable was attached using double sided tape 
and Hypafix (BSN Medical Limited, Hull, UK) and was programmed to capture with a 
sampling frequency of 100Hz (16 bit resolution, range ±8g). Recorded signals were stored 
locally on the sensor’s internal memory (512MB) as a raw binary file and then downloaded 
upon the completion of each testing session. Participants were provided with additional 
adhesives and attachment instructions for the duration of the 7-day free-living assessment, 
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and received a prepaid envelope and instructions for the return of the wearable to their host 
centre. Participants were informed that the wearable was shower-resistant but could not be 
submerged in water (i.e. in a bath/swimming), and that it should remain in place throughout 
the duration of the week. They were also provided instructions on how to reattach the 
wearable in the event it was removed or came off by itself.  
Gait assessment  
Participants were required to complete three gait assessments (Figure 1); two clinic based 
assessments (Day 1 and Day 169) and one free-living assessment as described above 
(beginning on day 85). Clinic assessments of gait included:  a straight line walk over a 
distance of 6 or 10m – depending upon availability of clinic space.  This was repeated 4 times 
in centres employing 10m walks, and 6 times in centres employing 6m walks under single-
task conditions. Assessment of free-living gait involved participants wearing the wearable on 
their lower back for 7-days. During this time, participants were instructed to go about normal 
activities as usual.  Gait outcomes were derived from a theoretical model [15] and included a 
range of characteristics sensitive to cognition [4]. 
<Insert Figure 1>  
Clinical and Neuropsychological Assessment 
Participants were also required to undergo a cognitive testing battery, here we report a limited 
set of tests with which we compare to gait measures. Participants were scored on the Mini 
Mental State Exam (MMSE) to provide a score of global cognition [24] and the Clinical 
Dementia Rating Scale (CDR) to rate the severity of dementia [25]. Participants also 
completed the Clock Drawing Executive Test (CLOX), a measure used to identify executive 
impairment [26]. Additionally, participants were scored on the Bristol Activities of Daily 
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Living Scale (BADLS) to identify impairments in activities of daily living [27] and the 
Geriatric Depression Scale (GDS), to identify depressive symptoms [28]. 
Data transfer from individual sites 
Raw acceleration data for both clinic-based and free-living assessments, along with 
pseudonymised patient information were transferred from external sites to Newcastle 
University using a commercially available cloud storage-system (Dropbox, Dropbox Inc.). 
This system is the most popular cloud based data transfer program [29], and has critical 
appraisal for robust in-built security measures [30]. All site-specific research staff were 
required to create a user account and to join a secure ‘shared’ folder with the gait 
correspondent at Newcastle University. Data were uploaded and shared immediately after 
completing a testing session and a confirmation email was provided to external sites after the 
data was downloaded to the secure databases at Newcastle University. 
Outcomes 
Gait outcomes chosen were based on a theoretical model of gait derived from principal 
component analysis [15] to allow exploration of a wide yet comprehensive range of variables 
(see Figure 1). It has previously been demonstrated in older adults and validated in 
Parkinson’s disease. Clinic based assessments of micro gait characteristics were derived as 
follows. Temporal algorithms identify initial contact (IC) and final contact (FC) events within 
the gait cycle. These are estimated from the filtered vertical accelerations by a Gaussian 
continuous wavelet transform (CWT) [31] which allows for timing estimations. Micro 
(spatiotemporal) outcomes are estimated using IC/FC events along with an inverted 
pendulum model [32]. Using the relationship between time and length (Eqn 1.), accurate 
estimations of gait velocity can then be provided (taken from Del Din and colleagues [33]). 
Variations of characteristics such as variability and asymmetry calculations facilitate a 
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detailed investigation of the step-to-step fluctuations and inter-limb coordination, 
respectively. Variability was estimated from the standard deviation between all steps. 
Asymmetry was determined as the absolute difference between left and right steps (Eqn 2) 
[31]. 
Step Length = 2 √2lh − ℎ2     (1) 
 
   (2) 
 
For 7-day free-living gait assessments a logical heuristics paradigm was embedded into 
walking bout identification and quantification algorithms.  Macro (behavioural) gait 
characteristics such as volume of time spent walking and number of bouts performed were 
generated based on the walking bouts detected across all days. In addition a set of non-linear 
descriptors were also derived, including: (i) shape and power-law distribution (alpha, α) 
based on a logarithmic scale from their density and length and (ii) the within bout variability 
(S2) estimated using a maximum likelihood technique [34]. Alpha refers to the distribution of 
total walking time, describing a ratio between long and short walking bouts. Higher alpha 
values means walking time is made up of proportionally more short bouts, while low alpha 
values means it is made up of proportionally more long bouts.    
Data Analysis 
Descriptive analysis was taken of both clinic and free-living data. Mann Whitney U tests 
were employed to assess differences between gait at the first and second visit. The 
relationship between cognition (as measured by the MMSE and CLOX 1 and 2) and gait (as 
measured by micro gait characteristics in Time 1, micro and macro gait characteristics in 
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free-living data) was explored using Spearman’s Rho. Preliminary analyses were performed 
to identify correlations between age and sex and the variables of interest – no correlations 
were found.   
Results 
Twenty participants were successfully recruited (see Table 1). Participants were removed 
from analysis at Time 1 due to problems with adherence to data collection protocol (n=2) and 
noisy signal due to incorrect sensor placement (n=1); and at Time 2 due to problems with 
adherence to data collection protocol (n=2) and noisy signal (n=1). Participants’ free-living 
gait data was removed from analysis due to failure to complete full seven day gait assessment 
(n=2), problems with adherence to data collection protocol (n=1), and a monitor was lost in 
the post (n=1). Table 1 provides the success rates for participant recruitment, and Table 2 
provides the number of participants for each time point within the study. Overall, from our 20 
participants, we had 83% completion of all data. 
<Insert Table 1> 
Demographics and cognitive measures for Time 1, Time 2 and free-living assessment for all 
subjects are provided in Table 2. Participants were older adults (mean age at baseline: 67 
years) with very mild Alzheimer’s disease impairment (mean MMSE score at baseline: 25; 
CDR: 0.9). Participants were not depressed (mean GDS score at baseline: 2/15) with minor 
impairments in activities of daily living (mean BADLS at baseline: 3/60) and executive 
function (mean CLOX1 and CLOX2 at baseline: 11/15 and 13/15 respectively).  
<Insert Table 2> 
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Clinic-based Data 
As previously detailed current algorithmic methods facilitate the generation of three of these 
characteristics in combination with 11 other discrete outcomes (see Table 3). No significant 
differences in gait were found between the first and second visit.  
<Insert Table 3>  
Free-living Data 
The logical heuristics algorithms for detection and quantification of walking bouts, and the 
linear and non-linear macro analysis were able to extract all three of these parameters with 
the addition of several potentially more sensitive measures (see Table 4). Data in Table 3 also 
provides micro characteristic gait outcomes derived from data collected in both clinic and 
free-living conditions throughout the feasibility study. We have also included a similarly 
aged control group from previous works following the same protocol – this is to provide a 
descriptive comparison regarding expected outcomes from a cognitively intact older 
population.   
<Insert Table 4>  
Relationship of clinical and free-living gait outcomes and cognitive function 
Clinical gait outcomes and cognition 
There was a strong negative correlation  between executive function (CLOX 1) and stance 
time, as measured in the clinic, RHO= - .539, p = .026, with higher levels of executive 
function associated with shorter stance time (strength of correlation interpreted according to 
Cohen [35]’s guidelines).  
Gait in mild Alzheimer’s disease 
12 
 
Free-living gait outcomes and cognition 
In free-living gait, there was a strong negative correlations between global cognition 
(MMSE) and step velocity, RHO = - .513, p = .042, and step length, RHO = - .519, p = .039, 
with lower MMSE scores associated with slower velocity and longer step length. There was a 
strong positive correlation between global cognition and step velocity variability, RHO = - 
.522, p = .038, with lower MMSE scores associated with higher variability. There was also a 
strong negative correlation between global cognition and number of daily bouts, RHO = - 
.595, p = .015, with lower MMSE scores associated with more daily bouts. Table 5 outlines 
all associations between cognitive and gait variables.  
Discussion 
The aim of this study was to determine the acceptability and feasibility of gait assessment in 
the clinic and the home using body-worn sensors in a dementia population. This study is 
novel in reporting both micro and macro gait outcomes in both the clinic and the home in a 
mild AD cohort across multiple sites nationally. Outcomes reported were comprehensive and 
clinically appropriate measures for both micro, looking at aspects of pace, variability, rhythm, 
asymmetry and postural control, and macro gait characteristics, looking at aspects of volume, 
pattern and variability of walking behaviours. This allows a widely representative picture of 
gait, which is necessary when considering gait’s potential clinical utility.  
Data were successfully collected from the majority of participants; demonstrating people with 
mild AD can complete clinical gait assessments and the utility of body-worn sensors as a 
non-invasive clinical tool that can quantitatively assess gait over prolonged periods. This 
study two lab gait assessments and one free-living assessment; this has not previously been 
done in the literature [18-20, 22]. No significant differences were found between the first and 
second visits; this may be due to the short time period between visits and the increased 
Gait in mild Alzheimer’s disease 
13 
 
familiarity with testing conditions. However, the majority of participants attended the follow-
up visit, showing willingness to undergo clinical gait assessment multiple times. Previous 
research has also found that body-worn sensors generally elicit positive feedback from 
participants, noting that they are comfortable and easy to wear.  
Although this study did not collect data from controls, inferences can be made from a 
previous data set of similar aged controls using the same body-worn sensors and derived gait 
outcomes as seen in Table 3 [17]. Regarding micro gait characteristics, within the clinic 
people with mild AD dementia demonstrated impairment across all domains; they walked 
more slowly and were more asymmetrical with impaired variability and postural control of 
gait compared to this reference control group. This indicates that gait is a potentially useful 
discriminatory tool between dementia and cognitively intact older adults. These findings were 
not as prominent in free-living gait assessment, possibly due to familiarity of home 
environment or due to increased complexity of free-living gait (i.e. environmental demands, 
obstacles, turning, walking while engaging in multiple activities [36]). For example, controls 
may engage in more complex walking activities such as large grocery trips or longer 
recreational walks, while people with dementia may stay closer to home and only engage in 
familiar activities they feel confident engaging in. The sample size is however very small and 
larger groups are needed to explore differences in free-living gait across group.  Further 
research is necessary to assess the potential of free-living gait as a useful complementary 
diagnostic marker for dementia.  
Another interesting finding was the reported average daily step count of 14,983 and average 
walking time of 220 minutes – almost 5000 steps and 70 minutes over the recommended 
daily step goal and time engaging in physical activity for adults respectively [37]. This goes 
against the norm, with the literature generally reporting approximately 6000 steps a day in 
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studies using a pedometer [38]. Although this could be due to a small group of research-
enthused participants, different sensors, such as pedometers, use different bout lengths to 
identify walking (i.e. some might identify over 60 seconds of activity as walking [39], others 
may identify over 10 steps as walking). This is considered problematic, as 90% of walking 
takes place in under 60 second bouts [14]; a higher cut-off threshold can therefore miss data 
and report lower step counts. Del Din, et al. [14] report a difference of approximately 7,500 
steps when using a > 60 second cut-off threshold compared to including all walking bouts. 
Gietzelt, et al. [22] found controls had a higher number of walking bouts compared to people 
with dementia; however, the study only included walking bouts > 20 seconds. For patient 
populations, it could be argued that including all walking bout lengths is beneficial in order to 
provide a truer picture – people with dementia may spend more time in short bouts of 
walking compared to long bouts.  Adopting a previously validated algorithm and data 
analysis process, this study identified walking as three or more steps with no minimum 
resting period [16, 17]. We propose the differences in the average daily activity demonstrated 
in this study and previous studies is due to a more sensitive measure of walking and a high 
proportion of steps taking place in short bouts of walking.  
As previously stated, strong associations between gait and cognition have been established, 
along with suggestions that gait impairment predicts cognitive decline [3, 4, 6, 40, 41]. This 
study similarly found correlations between global cognition and characteristics of pace and 
variability in free-living gait and a relationship between executive function and temporal 
characteristics of gait in the clinic. Lower cognitive scores were associated with slower pace 
and impaired timing and variability. Although these findings reflect previous literature, it was 
expected that a stronger relationship would be seen between gait and cognition in the clinic. 
This may become more obvious as cognitive impairment progresses; this particular cohort 
was still very early stage AD. Additionally, these cognitive measures were employed as they 
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are commonly used in clinics – more sensitive and specific measures used during in-depth 
neuropsychological testing may have produced stronger results. It was also found that lower 
cognitive scores were associated with more daily bouts of walking – our participants may 
have been taking an increased number of short bouts. Future research should look at this in 
relationship to variability of bout length and alpha, the ratio of long to short bouts, scores to 
better understand its meaning.  
Limitations and recommendations for the future  
Several key considerations for future research should be discussed. This study was a multi-
centre study, which led to between-site differences in gait protocol and data collection. Body-
worn sensors have the ability to assess sensitive and specific measures of gait, negating the 
need for a more technical gait laboratory and team of experts on-site. However, it is 
imperative that protocols are performed uniformly across sites in order to reduce 
heterogeneity. Therefore, when adopting this approach, fidelity to protocol should be 
regularly ascertained. Data was also lost during the study. This was not due to participants, 
but largely due to problems with the data collection protocol – this is an important outcome 
from this feasibility study, highlighting the need for efficient and regular training and 
refresher courses for research staff regarding use of technology and implementation of 
protocols. Clinic-based protocols differed in length of intermittent walks (either 6m or 10m). 
This was influenced by availability of space. Although it is recommended that longer walks 
provide more sensitive measures of steady state gait, only one centre could provide such a 
space. Therefore, it may be more feasible for future research to use shorter walks (6m or less) 
standardised across centres to ensure more accurate data pooling. It has also been shown that 
dual-task gait is a sensitive predictor of dementia [42, 43]; future research should encapsulate 
a dual-task protocol to improve gait’s utility as a clinical biomarker. Although the core aim of 
this study was to assess feasibility of such studies, the findings were limited by the small 
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sample size and lack of a control group for comparative purposes. Therefore, these findings 
are only preliminary. A larger sample and comparison with a healthy older adult control 
cohort will facilitate and strengthen data interpretation to determine utility of gait as a clinical 
biomarker in early stages of cognitive impairment and prodromal dementia. This will form 
part of the main DFP study. 
Clinical Implications 
Body-worn sensors can provide an enriched picture of an individual’s gait function and 
habitual walking activities that could act as a complementary diagnostic tool for clinicians. 
Clinical use of body-worn sensors in annual health assessments could track gait changes over 
time and act as a red flag for cognitive impairment. The ability to use these sensors in a home 
environment has added benefit because it provides continuous data over prolonged time 
periods which is more representative of gait rather than a one-off assessment, and reduced 
need to attend for assessment [14].  Free-living gait also captures environmental and 
cognitive challenges not seen in controlled clinical settings, and may provide a more realistic 
picture of gait without confounding factors such as observer bias and unfamiliar testing 
conditions [14]. Assessment of macro gait characteristics can also provide an easily 
understandable insight into changes in behaviour related to cognitive decline. Physical 
inactivity has been associated with dementia but reports are limited by use of self-report 
measures, which may be biased and unreliable [44]. Body-worn sensors could provide 
objective insights into volume and patterns of walking activity across healthy older adults to 
dementia populations [14]. This could also improve current physical rehabilitation strategies 
as interventions can be personalised to habitual activity [45].  
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Conclusion 
In conclusion, it is feasible to assess quantitative gait characteristics in both the clinic and the 
home in a cognitively impaired cohort. Going forward, care to standardise training and assess 
fidelity are important. Body-worn sensors hold great potential as a clinical tool that can 
provide a personalised picture of individual’s current gait function and could map changes 
across time. Future research aims to assess clinic and free-living gait in a cohort of prodromal 
Alzheimer’s disease as part of a larger study establishing a range of clinical biomarkers for 
dementia.  
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Figure 1: (a) Example of body worn monitor placement for both the clinic based and free-living data collection 
on L5 centrally located on the lower back; (b) Gait protocols for clinic and home based assessments for the 
D&FP feasibility study; (c) The raw vertical acceleration signal segmented into walking bouts (d) Left; 
Example of gait characteristic extraction from walking bouts: detecting initial contacts (black stars) and final 
contacts (white circles). Right:  Identification of walking bouts (black bars) from free-living data from which 
gait characteristics are extracted; (e) Left: Conceptual model of gait representing domains and 14 gait micro 
characteristics. Right: Macro characteristics of gait described by domains of volume, pattern and variability.  
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Table 1: Success rates of data collection and analysis across the six participating centres. 
Centre 
Participants 
Recruited 
Gait Assessments Collected 
(Analysed) 
Success Rate 
(n) Day 1 Day 85 Day 169 Collected Analysed 
1 4 4 (3) 3 (3) 3 (3) 10/12 (83%) 9/10 (90%) 
2 3 3 (2) 3 (3) 3 (3) 9/9 (100%) 8/9 (89%) 
3 4 4 (4) 4 (4) 4 (4) 12/12 (100%) 12/12 (100%) 
4 4 4 (4) 4 (4) 4 (4) 12/12 (100%) 12/12 (100%) 
5 2 2 (2) 2 (2) 2 (2) 6/6 (100%) 6/6 (100%) 
6 3 3 (2) 3 (0) 2 (1) 9/9 (89%) 3/9 (33%) 
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Table 2: Demographic and baseline assessment information for study participants included in data analysis. 
  Time 1 (n=17) Time 2 (n=17) 7-day Free-living (n=16) 
Age (years) 67.41 (7.8) 68.5 (7.200) 70.9 (8.3) 
Sex (m/f) 9/8 7/10 8/8 
Height (m) 1.68 (0.09) 1.685 (0.089) 1.69 (0.09) 
MMSE (0-30) 25 (3) n/a n/a 
CDR (0 -3) 0.9(.3) n/a n/a 
BADLS (0-60) 3 (3) n/a n/a 
GDS (0-15) 2 (1) n/a n/a 
CLOX1 (0-15) 11 (4) n/a n/a 
CLOX2 (0-15) 13 (2) n/a n/a 
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Table 3: Micro gait characteristics (reported as either (mean  ± SD) or (median (interquartile range)) as per 
control reference data [17]) for clinic gait assessment (Time 1 and 2) and free-living gait assessment, as derived 
from a theoretical model of gait [15]. Control data has previously been published for both clinical and free-
living protocols and is used here as a reference to show expected findings in a healthy ageing cohort.  
  Clinical Gait Assessment Free-living Gait 
  Time 1 Time 2 
Control 
Reference 
One time only 
Control 
Reference 
Domain/Gait Characteristics  (n=17)  (n=17) (n=50) (n=16) (n=50) 
Pace           
Step Velocity (m/s) 0.976 ± 0.186 0.995 ± 0.181 1.393 ± 0.207 1.044 (0.146) 1.097 (0.48) 
Step Length (m) 0.559 ± 0.083 0.569 ± 0.075 0.726 ±0.095 0.61 (0.054) 0.601 (0.183) 
Step Time Variability (s) 0.049 (0.065) 0.032 (0.016) 0.073 (0.301) 0.169 (0.034) 0.175 (0.156) 
Swing Time Variability (s) 0.028 (0.046) 0.027 (0.019) 0.018 (0.133) 0.145 (0.017) 0.147 (0.125) 
Stance Time Variability (s) 0.055 (0.065) 0.033 (0.018) 0.022 (0.109) 0.179 (0.035) 0.188 (0.161) 
Variability (SD)           
Step Velocity Variability (m/s) 0.087 (0.07) 0.083 (0.051) 0.073 (0.301) 0.357 (0.048) 0.383 (0.494) 
Step Length Variability (m) 0.048 (0.043) 0.052 (0.045) 0.033 (0.096) 0.147 (0.019) 0.151 (0.079) 
Rhythm           
Step Time (s) 0.583 ± 0.061 0.579 ± 0.056 0.525 ± 0.047 0.61 (0.029) 0.593 (0.144) 
Swing Time (s) 0.420 ± 0.058 0.424 ± 0.060  0.371 ± 0.040 0.461 (0.041) 0.449 (0.113) 
Stance Time (s) 0.739 ± 0.067 0.730 ± 0.058 0.679 ± 0.061 0.762 (0.031) 0.741 (0.166) 
Asymmetry           
Step Time Asymmetry (s) 0.024 (0.035) 0.019 (0.024) 0.007 (0.140) 0.095 (0.006) 0.093 (0.086) 
Swing Time Asymmetry (s) 0.017 (0.021) 0.021 (0.016) 0.010 (0.126) 0.086 (0.01) 0.084 (0.064) 
Stance Time Asymmetry (s) 0.02 (0.025) 0.027 (0.018) 0.007 (0.140) 0.095 (0.009) 0.094 (0.086) 
Postural Control           
Step Length Asymmetry (m) 0.033 (0.026) 0.031 (0.031) 0.007 (0.060) 0.083 (0.015) 0.081 (0.043) 
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Table 4: Macro gait characteristics (median (interquartile range)) for free-living gait assessment 
Macro gait characteristics 7-day Free-living Activity (n=16) 
Total Daily Walk Time (mins) 214 (66) 
Total Daily Steps 13268 (2791) 
Total Daily Bouts 707 (233) 
Mean Bout Length (secs) 17 (4) 
Variability 0.829 (0.059) 
Alpha 1.627 (0.065) 
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Table 5: Relationships between cognition and micro characteristics of gait (Spearman’s coefficient (p value)). 
Significant correlations are highlighted in bold.  
 Clinical Gait Assessment (n=17) Free-living Gait Assessment (n=16) 
  MMSE CLOX1 CLOX2 MMSE CLOX1 CLOX2 
Pace 
             
Step Velocity (m/s) -.094 (.719) .195(.453) .141 (.589) -.513*  (.042) .161 (.552) .199 (.459) 
Step Length (m) -.219 (.398) -.017 (.947) .001 (.996) -.519* (.039) -.073 (.788) .033 (.903) 
Step Time Variability (s) -.355 (.161) -.283 (.271) -.137 (.599) -.043 (.874) .063 (.818) .130 (.632) 
Swing Time Variability (s) -.303 (.236) -.104 (.692) -.065 (.804) .012 (.965) -.048 (.861) -.023 (.934) 
Stance Time Variability (S) -.368 (.146) -.271 (.294) -.127 (.626) -.004 (.987) .089 (.742) .153 (.573) 
Variability (SD) 
 
            
Step Velocity Variability 
(m/s) 
-.421 (.092) -.073 (.781) -.009 (.973) -.522* (.038) .313 (.239) .275 (.303) 
Step Length Variability (m) -.253 (.328) 0.000 (1.000) .140 (.592) -.116 (.670) .269 (.313) .014 (.960) 
Rhythm 
 
            
Step Time (s) -.168 (.518) -.472 (.056) -.387 (.125) .187 (.488) -.289 (.278) -.234 (.383) 
Swing Time (s) -.102 (.698) -.290 (.258) -.251 (.331) .096 (.723) -.274 (.305) -.198 (.463) 
Stance Time (s) -.287 (.263) -.539* (.026) -.384 (.129) .212 (.431) -.244 (.362) -.131 (.628) 
Asymmetry  
 
            
Step Time Asymmetry (s) -.033 (.900) -.238 (.358) .009 (.973) -.251 (.349) -.009 (.974) .374 (.153) 
Swing Time Asymmetry (s) -.217 (.403) -.362 (.153) -.216 (.405) -.074 (.785) -.065 (.810) .275 (.303) 
Stance Time Asymmetry (s) .069 (.791) -.183 (.482) .041 (.875) -.196 (.468) -.006 (.983) .355 (.177) 
Postural Control  
 
            
Step Length Asymmetry (m) -.211 (.417) -.151 (.563) .024 (.926) -.393 (.132) .076 (.780) .035 (.898) 
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Table 6: Relationships between cognition and macro characteristics of gait (Spearman’s coefficient (p value). 
Significant correlations are highlighted in bold.  
  MMSE CLOX1 CLOX2 
Total Daily Walk Time (mins) -.436 (.091) -.077 (.776) -.015 (.956) 
Total Daily Steps -.350 (.184) -.083 (759) -.139 (.608) 
Total Daily Bouts -.595* (.015) .055 (.839) .047 (863) 
Mean Bout Length (secs) .087 (.747) -.229 (.393) .092 (.734) 
Variability .388 (.137) -.159 (.556) -.196 (.466) 
Alpha -.110 (.686) .138 (.609) .174 (.520) 
 
